Lundbeck Foundation makes hire for new investment department
The foundation, which owns the majority of pharmaceutical firm Lundbeck, has hired Kevin Dalgaard, who comes to the firm from a role in business development at Boehringer Ingelheim.
by christian bundgaard, translated by catherine brett
Earlier this year, the Lundbeck Foundation merged its two investment arms Emerge and Ventures together to form Biocapital, which focuses exclusively on early-stage life science startups.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
